Full Press Release Details
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors.
IDYA
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
Key Takeaway: IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma